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THE annexin lipocortin 1 is reported to mediate some
anti-inflammatory effects of glucocorticoids, but the
mechanisms of this mediation are incompletely under-
stood. The involvement of lipocortin 1 in glucocorticoid
inhibition of monocyte interleukin 1 (IL-I) release has
been investigated. Treatment of peripheral blood mono-
cytes with 2 lttg/ml lipopolysaccharide potently increased
IL-1[I release (p= 0.001) and dexamethasone (10
-7 M)
significantly reduced both resting and stimulated IL-I
release (p 0.009). A neutralizing monoclonal antibody to
lipocortin 1 (0.5-50.0 Itg/ml) was unable to inhibit this
effect and recombinant lipocortin I (2 x 10
-6 M) and 188aa
lipocortin 1 fragment (10-8-10
-6 M) had no effect. It is
concluded that lipocortin 1 is not involved in the
inhibition of monocyte IL-I release by glucocorticoids.
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Introduction
Lipocortin 1 (annexin 1) is a member of the
annexin family of calcium-phospholipid binding
proteins. 1’2 The production of lipocortin 1 is
induced by glucocorticoids in a number of
systems,
s-6 including human peripheral blood
mononuclear cells after in vivo exposure to
glucocorticoids.
7 Lipocortin 1 has been demon-
strated to have a number of anti-inflammatory
actions in both in vitro and in vivo systems,
sq6 but
the influence of this protein on cytokine production
is unknown. The anti-inflammatory activity of
lipocortin 1 in vivo has yet to be fully explained in
terms of specific actions.
Interleukin-1 (IL-1) is a potent pro-inflammatory
cytokine which is produced in a wide range of
tissues including tissue macrophages, peripheral
blood monocytes, brain, synovium, lung, gut, and
bone.
17 It is involved in the mediation of
inflammation in a diverse list of conditions
including rheumatoid arthritis. 18’19 The production
of IL-1 in inflammatory tissue sites is under the
control of regulatory and counter-regulatory
systems. The major inhibitors of IL-1 production
are the glucocorticoids, and it is now well
established that dexamethasone inhibits the induc-
tion of monocyte IL-1 release by bacterial
lipopolysaccharide (LPS) in a dose dependent
fashion,i The mechanisms of this inhibition are
complex and include translational, transcriptional
and post-transcriptional events.
21-23 An attractive
explanation for some of the anti-inflammatory
actions of lipocortin 1 would be the inhibition of
IL-1 release or activity, and the possibility that
lipocortin 1 is involved in the suppression by
(C) 1993 Rapid Communications of Oxford ktd
glucocorticoids of IL-lfl release is supported by
several observations. First, glucocorticoid inhibi-
tion of IL-1 release in some in vitro settings is
abrogated by cycloheximide, an inhibitor of protein
synthesis.
24 Secondly, nuclear run-off studies
suggest that glucocorticoid inhibition of the early
phases of monocyte IL-lfl release may occur
without effects on transcription of the IL-lfl gene.
22
The mechanism of transport of IL-lfl from the
cytoplasm to the extracellular environment is not
known, but IL-lfl does not appear to have a signal
peptide and is not transported via the Golgi
apparatus.
25 Annexins, often cytoskeletal associated,
have been reported in preliminary studies to be
implicated in cell membrane vesicle formation,
exocytosis, and secretion.26’27
The role of lipocortin 1 in the inhibition by
dexamethasone of IL-lfl release from peripheral
blood monocytes has been investigated using
recombinant lipocortin 1, a bioactive lipocortin 1
fragment, and a neutralizing antibody to lipocortin
1. It is reported that none of these agents impact
on LPS induced monocyte IL-lfl release, or the
suppression of it by glucocorticoids, and the
authors conclude that lipocortin 1 is not involved
in this action of glucocorticoids.
Materials and Methods
Reagents: Cells were cultured in RPMI 1640
(Gibco, UK) supplemented with penicillin, strepto-
mycin and L-glutamine (Gibco, UK) and with 10%
heat inactivated charcoal stripped foetal calf serum
(Flow, ICN Laboratories, UK). Cell washes were
performed with calcium and magnesium-free
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phosphate buffered saline with 0.16% glucose
(PBSG). Refolded recombinant human lipocortin 1
(rhLCl) and a neutralizing mouse monoclonal
antibody to human LC1 (1A) were kindly provided
by Dr J. Browning (Biogen, Cambridge, MA). A
bioactive N-terminal 188 amino acid fragment of
lipocortin 1 (1-188aa) was kindly provided by Dr
F. Carey, ICI Pharmaceuticals, Cheshire, UK. IL-lfl
ELISA were purchased from Cascade Biochem
(Reading, UK). Dexamethasone and LPS (Escher-
ichia coli, serotype 055:B5 lipopolysaccharide) were
purchased from Sigma (St. Louis, MO).
Monocyte separation: Peripheral venous blood was
drawn from healthy volunteers into heparinized
containers and diluted 1:1 with PBSG. Mono-
nuclear cells were separated by centrifugation on a
Histopaque 1077 (Sigma, St Louis, MO) density
gradient for 30 min at 400 g, washed in PBSG,
and resuspended at 5 106cells/ml in culture
medium with 10% FCS. Monocytes in this suspen-
sion were allowed to adhere to 10 cm Petri dishes
(Costar, Cambridge, MA) for 60 min at 37C and
5% CO2 in a humidified incubator. After non-
adherent cells were removed by vigorous pipetting
with medium, adherent cells were removed by
gentle scraping with a rubber ’policeman’ and
washing with cold PBSG. Adherent cells were
< 10% CD3 positive by flow cytometric analysis.
Cell culture: Monocytes were cultured in 1 106 cell
aliquots. Neutralizing antibody to lipocortin 1
(0.5-50/g/ml), control antibody P3 (50 #g/ml),
rhLC1 (2 x 10
-6 M) or 1-188aa fragment (2 x 10
-6
to 2 x 10
-8 M) were incubated with monocytes for
2h in 96-well plates at 37C and 5% CO2 in a
humidified incubator. Ceils were then resuspended
into 1 ml of medium in 24-well tissue culture plates
(Costar, Cambridge, MA) and LPS 2/2g/ml and/or
dexamethasone 10-7M added. Cells were cul-
tured for 48 h at 37C and 5% CO2 in a humidified
incubator and viability at this time was > 95%.
IL-lfl assay: Culture supernatants were obtained by
centrifuging plates at 400 x g" for 5 min and careful
aspiration. Supernatants contained < 1 x 104
cells/ml. Supernatants were stored at -70C until
assay. IL-I ELISA were performed according to
the manufacturer’s instructions and had a sensitivity
of 1 pg/ml.
Statistical analysis: Supernatant IL-lfl levels were
compared using the Wilcoxon signed ranks test, or
Mann Whitney U test when the number of pairs
was less than six. Values ofp less than 0.05 were
regarded as statistically significant.
Results
IL-1/was detected in the supernatants of untreated
monocytes (mean 623, S.E.M. 122 pg/ml, n 13).
In all experiments, LPS 2 #g/ml induced significant
increases in supernatant IL-lfl concentration (mean
2188, S.E.M. 298pg/ml, p 0.001, n 13).
Dexamethasone potently inhibited LPS induced
IL-lfl release in all experiments (mean 666,
S.E.M. 94pg/ml, p-- 0.009, LPS vs LPS plus
dexamethasone, n 13) (Figs 1-3). Dexametha-
sone 10
-7 M also inhibited the levels of IL-lfl in the
supernatants of non-LPS treated monocytes (mean
291, S.E.M. 85 pg/ml, p 0.009, dexamethasone
treated vs untreated, n= 7, Fig. 1 and 2).
Pretreatment of monocytes with neutralizing
antibody to lipocortin 1 in doses of 0.5-50.0/g/ml
had no effect on the inhibitory action of
dexamethasone 10-7M on IL-I release (Fig. 1).
Pretreatment of monocytes with rhLC1 2 x 10
-6 M
had no suppressive effect on non-LPS treated
monocyte IL-lfl release, nor on the increase in
IL-I] release induced by LPS (Fig. 2). Pretreatment
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FIG. 1. Monocyte IL-lfl release: effects of neutralizing antibody to
lipocortin 1. Peripheral blood monocytes were cultured for 48 h in the
presence of bacterial lipopolysaccharide 2 #g/ml (LPS), dexamethasone
10-7 M (DEX), anti-lipocortin antibody 0.5-50/g/ml (1A) and/or
control antibody (P3), and the IL-lfl concentration in culture
supernatants measured by ELISA. LPS induced a marked increase in
IL-lfl release (p= 0.001) which was suppressed by dexamethasone
(p= 0.009). Dexamethasone also inhibited resting (non-LPS-treated)
monocyte IL-lfl release (p= 0.009). Anti-lipocortin antibody had no
effect on the ability of DEX to suppress this response.
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FIG. 2. Monocyte IL-1 fl release: effects of recombinant human lipocortin
1. Peripheral blood monocytes were cultured for 48 h in the presence of
LPS 2#g/ml, dexamethasone 10-7M (DEX), and recombinant human
lipocortin 2 x 10-6 M (rHLC-1) and the IL-lfl concentration in culture
supernatants measured by ELISA. rhLC-1 did not reproduce the inhibition
of monocyte L-1/Y release observed with dexamethasone.
50 Mediators of Inflammation. Vol 2.1993Lipocortin and interleukin release
3000
2000
1000
+ + + + +
2.0 0.02 0.2 2.0
LPS (2 lig/ml)
1-188 (IM)
DEX (10 M)
FIG. 3. Monocyte IL-lfl release: effects of 188aa N-terminal fragment of
lipocortin 1. Peripheral blood monocytes were cultured for 48 h in the
presence of LPS 2/g/ml, dexamethasone 10-7 M (DEX), and N-terminal
188 amino acid lipocortin fragment 2 x 10-8-2 x 10-6 M (1-188), and
the IL-lfl concentration in culture supernatants measured by ELISA.
1-188 did not reproduce the inhibition of monocyte IL-lfl release
observed with dexamethasone.
of monocytes with the 1-188aa lipocortin 1
fragment at concentrations of 2 x 10-SM to
2 x 10
-6 M similarly had no effect on untreated or
LPS treated monocyte IL-lfl release (Fig. 3).
Discussion
Evidence from animal models suggests that
lipocortin 1, a member of the annexin family of
calcium-phospholipid binding proteins, may be a
mediator of some of the anti-inflammatory actions
of glucocorticoids. 1’2 The production of lipocortin
1 has been shown to be induced by glucocorticoids
in a number of in vitro and in vivo studies.>7
Additionally, lipocortin 1 has been demonstrated to
mimic many in vitro actions of glucocorticoids,
including inhibition of natural killer cell activity
and antibody dependent cell-mediated cytotoxicity,
inhibition of reaction oxygen species generation,
and inhibition of prostaglandin and thromboxane
release.
81 Exogenous lipocortin 1 and bioactive
fragments of lipocortin 1 have, furthermore, been
demonstrated to exert anti-inflammatory activity in
vivo in a number of animal models of inflamma-
tion.
11-16
The results reported in this paper do not support
a role for lipocortin 1 in the suppression of IL-lfl
release by monocytes. Lipocortin 1 may, however,
be involved in the mediation of glucocorticoid
inhibition of the actions of IL-1, rather than its
production or release. A model for this hypothesis
exists in the hypothalamo-pituitary-adrenal axis.
IL-1 is produced in the pituitary, IL-1 receptors
have been demonstrated in pituitary cell cultures,
and circulating IL-1 is active in the pituitary where
it is involved in the regulation of the hypothalamo-
pituitary-adrenal axis response to inflammation.2-3
Lipocortin 1 has been demonstrated in the rat
pituitary,
31 and intracerebroventricular (i.c.v.) infu-
sion of lipocortin 1 or the 1-188aa peptide fragment
of lipocortin 1 is associated with a reduction in the
pyrogenic response to i.c.v. IL-1,14 strongly
suggesting that lipocortin 1 can directly inhibit
actions of IL-1. In addition, IL-1 increases
phospholipase A2 (PLA2) activity and leukocyte
prostaglandin release,17’32 while lipocortin 1 reduces
the production of prostaglandins via inhibition of
PLA2 activity, probably by binding to its
substrate.
33 In contrast, prostaglandins have been
reported to inhibit the production of IL-1 by
monocytes, possibly as part of an autocrine
feedback network. 32’34 Potential effects of lipocortin
1 on IL-1 release or action may be reversed by its
effect on prostaglandins. These suggestions of an
interaction of IL-1 and lipocortin 1 are of course
conjectural, and further research on the area of
annexin-cytokine interactions is needed.
In summary, lipocortin 1 is a glucocorticoid
induced protein whose anti-inflammatory activity
remains incompletely understood. A possible
mechanism of action of lipocortin I is the inhibition
of IL-1 release, possibly through effects on its
secretion. In studies with recombinant lipocortin 1,
a bioactive lipocortin 1 fragment, and neutralizing
antibodies to lipocortin 1, the authors have been
unable to demonstrate evidence that lipocortin 1 is
involved in the suppression by glucocorticoids of
the release of IL-1/3 by human peripheral blood
monocytes.
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